Page last updated: 2024-08-24

diphenylcyclopropenone and Nail Diseases

diphenylcyclopropenone has been researched along with Nail Diseases in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (50.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (33.33)	24.3611
2020's	1 (16.67)	2.80

Authors

Authors	Studies
Abedini, R; Aryanian, Z; Daneshmand, R; Ghandi, N; Hatami, P; Nasimi, M; Vance, TM	1
Pires, MC; Ribeiro, CP; Souza, BCE; Swiczar, BCC	1
Kim, JS; Kim, TL; Park, HK; Seo, HM	1
Aldrige, RD; Gordon, PM; Hunter, JA; McVittie, E	1
Rampen, FH; Steijlen, PM	1
Boezeman, JB; Happle, R; Perret, CM; van Baar, HM; van der Steen, PH	1

Trials

2 trial(s) available for diphenylcyclopropenone and Nail Diseases

Article	Year
A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata. International immunopharmacology, 2021, Volume: 99 Topics: Adolescent; Adult; Age of Onset; Alopecia Areata; Anthralin; Chronic Disease; Cyclopropanes; Drug Therapy, Combination; Female; Hair; Humans; Immunotherapy; Male; Middle Aged; Nail Diseases; Prospective Studies; Treatment Outcome; Young Adult	2021
Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months' follow-up. The British journal of dermatology, 1996, Volume: 134, Issue:5 Topics: Administration, Cutaneous; Adult; Age of Onset; Alopecia Areata; Cyclopropanes; Female; Follow-Up Studies; Humans; Hypersensitivity, Immediate; Male; Nail Diseases; Prognosis; Treatment Outcome	1996

Article

Year

A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata.

International immunopharmacology, 2021, Volume: 99

Topics: Adolescent; Adult; Age of Onset; Alopecia Areata; Anthralin; Chronic Disease; Cyclopropanes; Drug Therapy, Combination; Female; Hair; Humans; Immunotherapy; Male; Middle Aged; Nail Diseases; Prospective Studies; Treatment Outcome; Young Adult

2021

Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months' follow-up.

The British journal of dermatology, 1996, Volume: 134, Issue:5

Topics: Administration, Cutaneous; Adult; Age of Onset; Alopecia Areata; Cyclopropanes; Female; Follow-Up Studies; Humans; Hypersensitivity, Immediate; Male; Nail Diseases; Prognosis; Treatment Outcome

1996

Other Studies

4 other study(ies) available for diphenylcyclopropenone and Nail Diseases

Article	Year
Diphenciprone as a therapeutic alternative to exuberant periungual warts. Anais brasileiros de dermatologia, 2018, Volume: 93, Issue:2 Topics: Adolescent; Cyclopropanes; Female; Fingers; Humans; Immunologic Factors; Nail Diseases; Treatment Outcome; Warts	2018
What factors affect the duration of treatment with diphenylcyclopropenone immunotherapy for common warts? Dermatologic therapy, 2018, Volume: 31, Issue:6 Topics: Adolescent; Adult; Child; Cyclopropanes; Drug Administration Schedule; Facial Dermatoses; Female; Humans; Immunologic Factors; Immunotherapy; Male; Nail Diseases; Remission Induction; Retrospective Studies; Skin; Time Factors; Treatment Outcome; Warts; Young Adult	2018
Diphencyprone in the management of refractory palmoplantar and periungual warts: an open study. Dermatology (Basel, Switzerland), 1996, Volume: 193, Issue:3 Topics: Adjuvants, Immunologic; Administration, Cutaneous; Adolescent; Adult; Aged; Cyclopropanes; Dermatologic Agents; Drug Administration Schedule; Female; Follow-Up Studies; Foot Dermatoses; Hand Dermatoses; Humans; Hypersensitivity, Delayed; Male; Middle Aged; Nail Diseases; Remission Induction; Warts	1996
Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. Journal of the American Academy of Dermatology, 1991, Volume: 24, Issue:2 Pt 1 Topics: Adolescent; Adult; Aged; Alopecia Areata; Child; Child, Preschool; Cyclopropanes; Female; Humans; Immunotherapy; Male; Middle Aged; Nail Diseases; Prognosis; Sleep Wake Disorders	1991